Avalon Pharma Signed Deal to License Tirzepatide
The agreement secures rights for Avalon Pharma to bring the diabetes medication to patients in Saudi Arabia and the MENA region.
Updated on Oct. 11, 2026 in Diabetes
Live Poll
Does expanding local access to generic versions of high-cost medications improve healthcare in your community?
Avalon Pharma has entered into a licensing agreement with OneSource Specialty Pharma to register and commercialize the GLP-1 drug Tirzepatide. The deal expands access to various dosage strengths across the Middle East and North Africa.
Why it matters
This partnership aims to broaden the availability of metabolic disease treatments within the region while supporting long-term regional health initiatives. It marks a strategic expansion of Avalon Pharma's portfolio in the diabetes care sector.
The agreement covers six specific Tirzepatide dosage strengths ranging from 2.5 mg to 15 mg. Revenue projections suggest at least 800 million SAR will be generated in the first five years, though exact timelines are contingent upon the expiration of relevant patents.
The players
Avalon Pharma
A pharmaceutical company focused on the development and marketing of products for diabetes and metabolic diseases.
OneSource Specialty Pharma
An India-based pharmaceutical entity specializing in the manufacturing and supply of medical products.
The details
Tirzepatide is a GLP-1 receptor agonist used in the management of diabetes and metabolic conditions. Under the agreement, Avalon Pharma will serve as the marketing authorization holder and has the option to request technology transfer for local manufacturing after the product launches. The deal is set for an initial 10-year term with automatic annual renewals.
Timeline
The license agreement was officially signed on October 8, 2026.
Contract values were calculated based on company revenues as of December 31, 2025.
Health Landscape
This partnership aligns with the strategic goals established by Saudi Arabia's Vision 2030, which seeks to improve public health and increase local pharmaceutical manufacturing capabilities. The move mirrors a broader trend of regional firms securing access to high-demand metabolic drugs through international partnerships.
Patients in the affected regions should discuss the future availability of this therapy with their endocrinologist or primary care physician. As commercialization plans depend on patent expirations, local physicians will be the best source for updates on when these specific formulations might reach local markets.
The takeaway
The licensing of Tirzepatide reflects an ongoing effort to improve access to GLP-1 medications for chronic metabolic health management. Keep track of updates from your local health authority regarding the regulatory approval and availability of new diabetes treatments in your area.
Further reading
For more information on the evolving landscape of blood sugar management, visit our Diabetes section.
Source note: This article includes information reported by Mubasher.
Live Poll
Does expanding local access to generic versions of high-cost medications improve healthcare in your community?
